Gisele Abreu Coelho

Mrs. Gisele Abreu Coelho

Université Paris-Saclay, Orsay, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGisele Abreu Coelho
Gisele Abreu Coelho
PSPhilippe-Henri Secrétan
Philippe-Henri Secrétan
LTLionel Tortolano
Lionel Tortolano
LCLoïc Charvet
Loïc Charvet
NYNajet Yagoubi
Najet Yagoubi
Studies have reported that the constituents of the wound microenvironment are likely to have critical roles in the degradation and fate of the polymeric matrix and the compounds dissolved in the wound dressing matrix. Thus, chronic wound assessment and the design of effective medical devices and drug products for wound care partly rely on an in-depth understanding of the wound microenvironment. The main aim of this review is to identify and discuss the different stages of chronic wound progression, focusing on the changes in the biochemical composition of the wound microenvironment, with particular attention given to venous leg ulcers (VLUs), as they are one of the most prevalent chronic wound aetiologies. The pathophysiology of venous ulcers is detailed, followed by a thorough review of what is known about the VLU microenvironment and its changes as a function of the evolution of the VLU. Simulating conditions for VLU are then discussed with the view of highlighting potentially relevant simulating media as a function of VLU evolution for a better assessment of biological safety, in particular medical devices intended to be in contact with these wounds.

30 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TBTahar Sif Eddine Bouchema
Tahar Sif Eddine Bouchema
MAMaxime Annereau
Maxime Annereau
VVVictoire Vieillard
Victoire Vieillard
RBRaphael Boquet
Raphael Boquet
GCGisele Abreu Coelho
Gisele Abreu Coelho
BDBernard Do
Bernard Do
Selumetinib is administered orally in capsule form and is indicated for the treatment of neurofibromatosis. To facilitate dosage adjustments, liquid preparations, such as solutions or suspensions, are to be developed. This led, first, to determine the stability profile of soluble or dispersed selumetinib and, secondly, to look for ways to stabilize the active substance. The degradation kinetics of selumetinib as a function of stress conditions were determined and compared. The degradation products were detected and identified by LC-HRMSn. In solution, selumetinib is sensitive to oxidation and degrades by photooxidation. In both cases, the side chain represented by the oxoamide group is concerned, leading to the formation of an amide derivative for the first case and an ester derivative for the second. The identification of such degradation mechanisms allowed us to study, in a targeted way, processes aiming at stabilizing the active molecule.